Protocol of a prospective, multicentre phase I study to evaluate the safety, tolerability and preliminary efficacy of the bispecific PSMAxCD3 antibody CC-1 in patients with castration-resistant prostate carcinoma

DSpace Repository

Protocol of a prospective, multicentre phase I study to evaluate the safety, tolerability and preliminary efficacy of the bispecific PSMAxCD3 antibody CC-1 in patients with castration-resistant prostate carcinoma

Author: Heitmann, Jonas S.; Walz, Juliane S.; Pfluegler, Martin; Kauer, Joseph; Schlenk, Richard F.; Jung, Gundram; Salih, Helmut R.
Tübinger Autor(en):
Heitmann, Jonas S.
Walz, Juliane S.
Pfluegler, Martin
Kauer, Joseph
Jung, Gundram
Salih, Helmut R.
Published in: Bmj Open (2020-08), Bd. 10, H. 10
Verlagsangabe: Bmj Publishing Group
Language: English
Full text: http://dx.doi.org/10.1136/bmjopen-2020-039639
ISSN: 2044-6055
DDC Classifikation: 610 - Medicine and health
Dokumentart: Artikel
Show full item record

This item appears in the following Collection(s)